Your browser doesn't support javascript.
loading
The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile.
Aragón-Herrera, Alana; Otero-Santiago, Manuel; Anido-Varela, Laura; Moraña-Fernández, Sandra; Campos-Toimil, Manuel; García-Caballero, Tomás; Barral, Luis; Tarazón, Estefanía; Roselló-Lletí, Esther; Portolés, Manuel; Gualillo, Oreste; Moscoso, Isabel; Lage, Ricardo; González-Juanatey, José Ramón; Feijóo-Bandín, Sandra; Lago, Francisca.
Afiliación
  • Aragón-Herrera A; Cellular and Molecular Cardiology Research Unit, Institute of Biomedical Research and Xerencia de Xestión Integrada de Santiago (XXIS/SERGAS), Santiago de Compostela, Spain.
  • Otero-Santiago M; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Institute of Health Carlos III, Madrid, Spain.
  • Anido-Varela L; Cellular and Molecular Cardiology Research Unit, Institute of Biomedical Research and Xerencia de Xestión Integrada de Santiago (XXIS/SERGAS), Santiago de Compostela, Spain.
  • Moraña-Fernández S; Cellular and Molecular Cardiology Research Unit, Institute of Biomedical Research and Xerencia de Xestión Integrada de Santiago (XXIS/SERGAS), Santiago de Compostela, Spain.
  • Campos-Toimil M; Cellular and Molecular Cardiology Research Unit, Institute of Biomedical Research and Xerencia de Xestión Integrada de Santiago (XXIS/SERGAS), Santiago de Compostela, Spain.
  • García-Caballero T; Group of Pharmacology of Chronic Diseases (CD Pharma), Department of Pharmacology, Pharmacy and Pharmaceutical Technology, University of Santiago de Compostela, Santiago de Compostela, Spain.
  • Barral L; Department of Morphological Sciences, University of Santiago de Compostela and Xerencia de Xestión Integrada de Santiago (XXIS/SERGAS), Santiago de Compostela, Spain.
  • Tarazón E; Group of Polymers, Department of Physics and Earth Sciences, University of La Coruña, La Coruña, Spain.
  • Roselló-Lletí E; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Institute of Health Carlos III, Madrid, Spain.
  • Portolés M; Cardiocirculatory Unit, Health Research Institute of La Fe University Hospital, Valencia, Spain.
  • Gualillo O; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Institute of Health Carlos III, Madrid, Spain.
  • Moscoso I; Cardiocirculatory Unit, Health Research Institute of La Fe University Hospital, Valencia, Spain.
  • Lage R; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Institute of Health Carlos III, Madrid, Spain.
  • González-Juanatey JR; Cardiocirculatory Unit, Health Research Institute of La Fe University Hospital, Valencia, Spain.
  • Feijóo-Bandín S; Laboratory of Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases, Institute of Biomedical Research and Xerencia de Xestión Integrada de Santiago (XXIS/SERGAS), Santiago de Compostela, Spain.
  • Lago F; Cardiology Group, Center for Research in Molecular Medicine and Chronic Diseases (CIMUS) and Institute of Biomedical Research of Santiago de Compostela (IDIS-SERGAS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain.
Front Pharmacol ; 13: 827033, 2022.
Article en En | MEDLINE | ID: mdl-35185578
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Front Pharmacol Año: 2022 Tipo del documento: Article País de afiliación: España
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Front Pharmacol Año: 2022 Tipo del documento: Article País de afiliación: España